Company intelligence / Profile preview
Greenovation Biotech GmbH
Heilbronn, Baden-Württemberg, Germany
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Received BfArM approval in September 2015 to start Phase I clinical trial for moss-aGal, their lead product for Fabry Disease. Preclinical studies showed promising results with respect to pharmacokinetics, pharmacodynamics, and biodistribution[6][10].
- Therapeutic areas
- OncologyHematologyRare Diseases
- Modalities
- Recombinant proteinsGlycoproteinsAntibodiesEnzymes
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Sartorius Stedim Biotech GmbHBayer Innovation GmbHAM-Pharma B.V.Dow Chemical CompanyArana
Beyond the preview
Go deeper on Greenovation Biotech GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Greenovation Biotech GmbH.